Jane Wu

8487093, Jul 16, 2013

Jan 15, 2009

12/812763

Timothy A. Blizzard - Princeton NJ, US
Helen Chen - Marlboro NJ, US
Candido Gude - Staten Island NY, US
Jeffrey D. Hermes - Warren NJ, US
Jason Imbriglio - Piscataway NJ, US
Seongkon Kim - Holmdel NJ, US
Jane Y. Wu - Marlboro NJ, US
Christopher J. Mortko - Hoboken NJ, US
Ian Mangion - Cranford NJ, US
Nelo Rivera - New Milford NJ, US
Rebecca T. Ruck - Jersey City NJ, US
Michael Shevlin - Plainfield NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 243/00
A61K 31/551

540556, 514221

Substituted bicyclic beta-lactams of Formula I: (I), are β-lactamase inhibitors, wherein a, X, Rand Rare defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with β-lactam antibiotics. In particular, the compounds can be employed with a β-lactam antibiotics (e. g. , imipenem, piperacillin, or ceftazidime) against microorganisms resistant to β-lactam antibiotics due to the presence of the β-lactamases.

20020165226, Nov 7, 2002

Apr 11, 2002

10/120723

Frank DiNinno - Old Bridge NJ, US
Jane Wu - Marlboro NJ, US
Seongkon Kim - Holmdel NJ, US
Helen Chen - Livingston NJ, US

C07D279/16
C07D265/36
C07D215/12
A61K031/5415
A61K031/536
A61K031/498
A61K031/47

514/224200, 514/230500, 514/249000, 514/311000, 544/051000, 544/105000, 544/353000, 546/176000

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

20040044226, Mar 4, 2004

Apr 15, 2003

10/399246

Frank DiNinno - Old Bridge NJ, US
Seongkon Kim - Holmdel NJ, US
Jane Wu - Marlboro NJ, US

C07D335/06
C07D495/02

549/023000, 549/362000

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynacomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

20100009957, Jan 14, 2010

Sep 24, 2007

12/442816

Timothy A. Blizzard - Princeton NJ, US
Helen Y. Chen - Marlboro NJ, US
Jane Yang Wu - Marlboro NJ, US
Seongkon Kim - Holmdel NJ, US
Sookhee Ha - Warren NJ, US
Christopher J. Mortko - Hoboken NJ, US
Narayan Variankaval - Plainsboro NJ, US
Anna Chiu - Redwood City CA, US

A61K 31/397
C07D 205/12
A61P 31/04

51421005, 540203

A class of 7-oxo-2,6-diazabicyclo-[3.2.0]-heptane-6-sulfonic acid compounds substituted at the two position of the bicyclic ring with a heterocyclylaminocarbonyl group or a carbocyclylaminocarbonyl group are β-lactamase inhibitors. The compounds and their prodrugs and pharmaceutically acceptable salts are useful in the treatment of bacterial infections in combination with β-lactam antibiotics. In particular, the compounds are suitable for use with β-lactam antibiotics (e.g., imipenem and ceftazidime) against micro-organisms resistant to β-lactam antibiotics due to the presence of the β-lactamases.

20180105518, Apr 19, 2018

Apr 4, 2016

15/562617

- Rahway NJ, US
Yi Heng Chen - Whippany NJ, US
Ping Liu - Westfield NJ, US
Dongfang Meng - Morganville NJ, US
Jane Yang Wu - Marlboro NJ, US
Chun Sing Li - Shanghai, CN
Zhiqi Qi - Shanghai, CN

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 471/04
C07D 417/12
C07D 487/04
C07D 403/12
A61P 25/00
A61P 35/00
A61P 9/10
A61P 17/06
A61P 7/02

The present invention is directed to bicyclic heteroaryl benzamide compounds of formulas (I): which are tropomyos-in-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

20180022747, Jan 25, 2018

Feb 12, 2016

15/550862

Dongfang MENG - Rahway NJ, US
Hong LI - Rahway NJ, US
Meng YANG - Rahway NJ, US
Manuel de Lera RUIZ - West Point PA, US
Sunita V. DEWNANI - Secaucus NJ, US
Tianying JIAN - Rahway NJ, US
Ting ZHANG - Rahway NJ, US
Louis-Charles CAMPEAU - Rahway NJ, US
Bart HARPER - Rahway NJ, US
Harold B. WOOD - Rahway NJ, US
Jiayi XU - Rahway NJ, US
Richard BERGER - West Point PA, US
Jane Yang WU - Rahway NJ, US
Robert K. ORR - Rahway NJ, US
Shawn P. WALSH - Kenilworth NJ, US
- Rahway NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 471/04
C07D 403/12
C07D 498/04
C07D 417/14
C07D 513/04
C07D 471/14
C07D 413/14

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.